Straits Times Index
3,300.00 -4.00 (-0.12%) S&P 500
5,487.03 +13.80 (+0.25%) Dow
38,834.86 +56.76 (+0.15%) Nasdaq
17,862.23 +5.21 (+0.03%) Bitcoin USD
66,030.10 +941.58 (+1.45%) CMC Crypto 200
1,373.97 -8.69 (-0.63%)
Kymera Therapeutics, Inc. (KYMR)
After hours:
| Previous close | 31.82 |
| Open | 31.70 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 30.77 - 31.89 |
| 52-week range | 9.60 - 45.31 |
| Volume | |
| Avg. volume | 499,625 |
| Market cap | 1.914B |
| Beta (5Y monthly) | 2.26 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Kymera Therapeutics Presents New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting
KT-333 demonstrated initial clinical proof of concept across multiple hematological malignancies, including complete responses in two patients with Hodgkin’s lymphoma Robust STAT3 knockdown and positive immunomodulatory effect achieved in blood and tumor KT-333 was well-tolerated with Phase 1 dose escalation ongoing and additional data expected in the second half of 2024 WATERTOWN, Mass., June 14, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutic
- GlobeNewswire
Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting
KT-253 demonstrates initial clinical proof of concept in patients with tumor types shown to be sensitive in preclinical models, including responses in MCC and AML Evidence of target engagement and potent upregulation of p53 pathway biomarkers even at the lowest dose levels in solid tumor and AML patients KT-253 was generally well tolerated without hematologic adverse events seen with traditional MDM2 small molecule inhibitors KT-253 Phase 1 study ongoing with additional data expected in the seco
- GlobeNewswire
Kymera Therapeutics to Participate in Upcoming June Investor Conferences
WATERTOWN, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the Company will participate in fireside chats at the following upcoming investor events: Jefferies 2024 Global Healthcare Conference in New York, NY on June 5 at 11:30 a.m. ET; andGoldman Sachs 45th Annual Global Healthcare Conference in Miami, FL on
